Steroid infusion using a spray tube after ESD for esophageal cancer
- Conditions
- esophageal cancer
- Registration Number
- JPRN-jRCT1061220099
- Lead Sponsor
- Goto Atsushi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
1. Patients diagnosed with esophageal cancer or suspected esophageal cancer by endoscopy and biopsy
2. Esophageal cancer is diagnosed as confined to submucosal infiltration by preoperative endoscopic diagnosis.
3. Patients who are expected to undergo esophageal ESD for esophageal cancer and resection of 3/4 or more of the luminal circumference but less than the entire circumference
4. Written consent has been obtained from the patient or legally acceptable representative after receiving a sufficient explanation about study participation.
(1) Patients with esophageal cancer whose major axis exceeds 5 cm
(2) Patients taking steroids before esophageal ESD
(3) Patients judged by the researcher's doctor to be inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint: stenosis rate in the spraying tube group and needle group
- Secondary Outcome Measures
Name Time Method Secondary endpoints: rate of adverse events, number of endoscopic balloon dilatations